Predicting recurrence using the clinical factors of patients with non-small cell lung cancer after curative resection

Journal of Korean Medical Science

Volumn 24, Issue 5, 2009, Pages 824-830

  Lee, Hyun Joo ^a   Jo, Jisuk ^c   Son, Dae Soon ^c   Lee, Jinseon ^c   Choi, Yong Soo ^b   Kim, Kwhanmien ^b   Shim, Young Mog ^b   Kim, Jhingook ^b,c  

^a University of Ulsan College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Samsung Medical Center   (South Korea)

Author keywords

Carcinoma; Non small cell lung; Prognosis; Recurrence

Indexed keywords

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; REGRESSION ANALYSIS; RISK FACTOR; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGRESSION ANALYSIS; RISK FACTORS; SURVIVAL RATE;

EID: 75349084716     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2009.24.5.824     Document Type: Article

References (17)

1. Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG,Harris CC. Molecular epidemiology of human cancer risk: geneenvironment interactions and p53 mutation spectrum in human lung cancer. J Pathol 1999; 187: 8-18.
2. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-7.
3. Nesbitt JC, Putnam JB Jr, Walsh GL, Roth JA, Mountain CF. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 1995; 60: 466-72.
4. Park I, Kim DJ, Chung KY, Kim KD, Joo HC. Risk factors for recurrence in completely resected pT1/2N1 non-samll cell lung cancer. Korean J Thorac Cardiovasc Surg 2005; 38: 421-7.
5. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-60.
6. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T, Shepherd F. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-97.
7. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in nonsmall cell lung cancer: a decade of progress. Chest 2002; 122: 1037-57.
8. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS, West M, Harpole DH Jr, Nevins JR. A genomic strategy to refine prognosis in earlystage non-small-cell lung cancer. N Engl J Med 2006; 355: 570-80.
9. Pfannschmidt J, Muley T, Bulzebruck H, Hoffmann H, Dienemann H. Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. Lung Cancer 2007; 55: 371-7.
10. Abel U, Berger J, Wiebelt H. CRITLEVEL: an exploratory procedure for the evaluation of quantitative prognostic factors. Methods Inf Med 1984; 23: 154-6.
11. Birim O, Kappetein AP, Waleboer M, Puvimanasinghe JP, Eijkemans MJ, Steyerberg EW, Versteegh MI, Bogers AJ. Long-term survival after non-small cell lung cancer surgery: development and validation of a prognostic model with a preoperative and postoperative mode. J Thorac Cardiovasc Surg 2006; 132: 491-8.
12. Harpole DH Jr. Prognostic modeling in early stage lung cancer: an evolving process from histopathology to genomics. Thorac Surg Clin 2007; 17: 167-73.
13. Padilla J, Calvo V, Penalver JC, Zarza AG, Pastor J, Blasco E, Paris F. Survival and risk model for stage IB non-small cell lung cancer. Lung Cancer 2002; 36: 43-8.
14. Charloux A, Hedelin G, Dietemann A, Ifoundza T, Roeslin N, Pauli G, Quoix E. Prognostic value of histology in patients with non-small cell lung cancer. Lung Cancer 1997; 17: 123-34.
15. Khan OA, Fitzgerald JJ, Field ML, Soomro I, Beggs FD, Morgan WE, Duffy JP. Histological determinants of survival in completely resected T1-2N1M0 nonsmall cell cancer of the lung. Ann Thorac Surg 2004; 77: 1173-8.
16. Okamoto T, Maruyama R, Suemitsu R, Aoki Y, Wataya H, Kojo M, Ichinose Y. Prognostic value of the histological subtype in completely resected non-small cell lung cancer. Interact Cardiovasc Thorac Surg 2006; 5: 362-6.
17. Yokouchi H, Kodama K, Higashiyama M, Takami K. Prognostic assessment of resected lung cancer based on the new international staging system: analysis by histologic types. Kyobu Geka 2000; 53: 899-904.